J. Randolph Hecht, MD, University of California, Los Angeles, CA, shares his highlights in gastrointestinal (GI) cancer from the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022), including data on a Phase II trial investigating botensilimab, an Fc-enhanced anti-CTLA-4, in combination with the anti-PD-1, balstilimab, in patients with microsatellite stable colorectal cancer (MSS CRC). Although patients with microsatellite instability-high (MSI-H) CRC have demonstrated significant sensitivity to checkpoint inhibitors, 97% of patients with MSS CRC are irresponsive. The combination of balstilimab with botensilimab demonstrated an overall response rate (ORR) of 22% in patients with MSS colon cancer. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.